AffyImmune Therapeutics scores $30m

AffyImmune Therapeutics Inc, a clinical stage biotechnology company, has raised $30 million in funding.

7 October 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles